Comparative Pharmacology
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORETON METHYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO TESTOSTERONE versus ORETON METHYL.
DEPO-TESTOSTERONE vs ORETON METHYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
50-400 mg IM every 2-4 weeks
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
None Documented
None Documented
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Category D/X
Category C
Androgen
Androgen